



## **WANTED!** INNOVATIVE TARGET ASSAYS

# Collaborative high quality screening with European Lead Factory resources

### **Unique, ultra-high throughput and high-quality advanced screening on your own drug target**

Pharmaceutical companies have vast libraries of compounds that can be screened in the hunt for potential medicines, but access has usually been highly restricted. It means that their value has not always been fully exploited in the search for promising drug candidates.

The European Lead Factory funds collaborative screening of compounds to assess their activity. The aim is to help contributors develop an Improved Hit List from a Qualified Hit List, with substantial cost savings and a very productive exchange of ideas. Target programme owners benefit from state-of-the-art facilities at the newly established European Screening Centre, based in Scotland and the Netherlands.

### **What's in it for you?**

Collaboration is the central theme of the European Lead Factory. By taking part as target programme owner, you can be part of a highly specialised team, and gain access to cutting edge facilities:

- uHTS against the unique Joint European Compound Collection:  
>300,000 novel small molecules in 2014, increasing to 500,000 by 2017 (available only via the European Lead Factory).
- Access rights, and 3-year exclusivity to exploit screening results.
- Highly sophisticated and qualified resources available for European academics and SMEs.
- Control of target programme progression.
- Business opportunities with established pharmaceutical companies.

**Find out how to submit your own programme: Go to [www.europeanleadfactory.eu/proposals](http://www.europeanleadfactory.eu/proposals)**



Disclaimer: Any information contained in this flyer is not binding any party and can in no event be used to replace, interpreted or complement the formally signed contractual documents governing the project, not limited to but including the Project Agreement, Grant Agreement and Third Party Access Agreements. For further information, please visit [www.europeanleadfactory.eu/proposals/legal-framework/](http://www.europeanleadfactory.eu/proposals/legal-framework/)

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.



European  
Lead Factory

## **WANTED!** INNOVATIVE COMPOUND LIBRARY DESIGNS

### Rewards for validated chemical scaffold ideas

#### **A non-profit initiative sponsored by the Innovative Medicines Initiative (IMI)**

The European Lead Factory is seeking high quality Library Design Proposals from European academics and SMEs. Payments are being made for promising, validated designs, following their successful translation into 50 or more compounds by one of our many world-class European partners' synthesis laboratories.

This is an opportunity to see lead molecules synthesised that have real potential to support future drug discovery, and to receive payment at the same time. If you have already demonstrated that your scaffold is synthetically tractable, our rapid and transparent web-based submission process will give you instant feedback, based on assessment against six criteria:

- Molecular properties (scored for drug-likeness with preferred  $\text{clogP} < 4$ )
- Structural features
- Novelty
- Diversity potential (ideally yielding >500 final compounds)
- Synthetic tractability
- Innovation

#### **What's in it for you?**

The level of the payment is determined by the degree of technical maturity, as assessed by an expert Compound Selection Committee. The highest payment of €5,000 is made for successful proposals that meet all of the following criteria:

- A scaffold synthesis already validated on a multi-gram scale
- Full experimental details and spectra provided for all intermediates for your validated synthesis
- Physical sample provided of >2g (>90% purity) of the key intermediate immediately prior to diversification
- Evidence of identity and purity provided for any derivatives that have been prepared from the key intermediate

**Find out how to submit your own programme:** Go to [www.europeanleadfactory.eu/proposals](http://www.europeanleadfactory.eu/proposals)